Active surveillance should be considered for select men with Grade Group 2 prostate cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Active surveillance should be considered for select men with Grade Group 2 prostate cancer ; volume:23 ; number:1 ; day:30 ; month:9 ; year:2023 ; pages:1-6 ; date:12.2023
BMC urology ; 23, Heft 1 (30.9.2023), 1-6, 12.2023
- Urheber
-
Pekala, Kelly R.
Bergengren, Oskar
Eastham, James A.
Carlsson, Sigrid V.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12894-023-01314-6
- URN
-
urn:nbn:de:101:1-2024020515334446708700
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:21 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Pekala, Kelly R.
- Bergengren, Oskar
- Eastham, James A.
- Carlsson, Sigrid V.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Active surveillance should not be routinely considered in ISUP grade group 2 prostate cancer
What should be considered during epicutaneous patch testing?
Who Should Be Considered for Islet Transplantation Alone?
Which patients should be considered for gene therapy
All Things Considered, Should Egalitarian Movements Accept Philanthropic Funding?
Powerpenia Should be Considered a Biomarker of Healthy Aging
Prostate MRI and artificial intelligence during active surveillance: should we jump on the bandwagon?
Hemodialysis dose and frequency should be considered in subgroup analysis
Failed oral immunotherapy should be considered as a risk factor for fatal anaphylaxis, and omalizumab treatment considered
Defining the quality of urban life: Which factors should be considered?
Response to: ‘Failed oral immunotherapy should be considered as a risk factor for fatal anaphylaxis, and omalizumab treatment considered’
Should development of Alzheimer’s disease-specific intravenous immunoglobulin be considered?
Active surveillance should not be routinely considered in ISUP grade group 2 prostate cancer
What should be considered during epicutaneous patch testing?
Who Should Be Considered for Islet Transplantation Alone?
Which patients should be considered for gene therapy
All Things Considered, Should Egalitarian Movements Accept Philanthropic Funding?
Powerpenia Should be Considered a Biomarker of Healthy Aging
Prostate MRI and artificial intelligence during active surveillance: should we jump on the bandwagon?
Hemodialysis dose and frequency should be considered in subgroup analysis
Failed oral immunotherapy should be considered as a risk factor for fatal anaphylaxis, and omalizumab treatment considered
Defining the quality of urban life: Which factors should be considered?
Response to: ‘Failed oral immunotherapy should be considered as a risk factor for fatal anaphylaxis, and omalizumab treatment considered’
Should development of Alzheimer’s disease-specific intravenous immunoglobulin be considered?
Active surveillance should not be routinely considered in ISUP grade group 2 prostate cancer
What should be considered during epicutaneous patch testing?
Who Should Be Considered for Islet Transplantation Alone?
Which patients should be considered for gene therapy
All Things Considered, Should Egalitarian Movements Accept Philanthropic Funding?
Powerpenia Should be Considered a Biomarker of Healthy Aging
Prostate MRI and artificial intelligence during active surveillance: should we jump on the bandwagon?
Hemodialysis dose and frequency should be considered in subgroup analysis
Failed oral immunotherapy should be considered as a risk factor for fatal anaphylaxis, and omalizumab treatment considered
Defining the quality of urban life: Which factors should be considered?
Response to: ‘Failed oral immunotherapy should be considered as a risk factor for fatal anaphylaxis, and omalizumab treatment considered’